Armata Pharmaceuticals, Inc.
ARMP
$5.41
-$0.41-7.05%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -19.29% | 10.70% | -5.22% | -7.55% | 84.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.29% | 10.70% | -5.22% | -7.55% | 84.67% |
| Cost of Revenue | -17.64% | -30.04% | -39.61% | -47.80% | -34.07% |
| Gross Profit | 16.86% | 40.25% | 48.15% | 55.54% | 49.47% |
| SG&A Expenses | 11.50% | -4.80% | -5.44% | 58.79% | 55.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.25% | -17.92% | -24.12% | -18.19% | -7.82% |
| Operating Income | 0.13% | 21.25% | 26.43% | 19.59% | 15.99% |
| Income Before Tax | -647.57% | -66,241.31% | -818.79% | -13.39% | 61.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -647.57% | -66,241.31% | -818.79% | -13.39% | 61.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -647.57% | -66,241.31% | -818.79% | -13.39% | 61.66% |
| EBIT | 0.13% | 21.25% | 26.43% | 19.59% | 15.99% |
| EBITDA | 1.32% | 22.58% | 27.78% | 20.83% | 17.15% |
| EPS Basic | -645.53% | -66,825.00% | -813.94% | -13.07% | 61.76% |
| Normalized Basic EPS | -15.48% | 4.72% | 9.82% | 3.65% | 1.16% |
| EPS Diluted | -473.78% | -593.56% | -197.55% | -16.24% | 43.78% |
| Normalized Diluted EPS | -27.62% | -35.03% | -2.46% | 14.10% | 11.51% |
| Average Basic Shares Outstanding | 0.77% | 0.41% | 0.22% | 0.16% | 0.19% |
| Average Diluted Shares Outstanding | -10.36% | -31.78% | -11.28% | 14.60% | 14.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |